Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Democratic Congress May Mean Greater Postmarket Focus, FDA Funding

This article was originally published in The Gray Sheet

Executive Summary

The rise of Reps. John Dingell (D-Mich.) and Henry Waxman (D-Calif.) to top committee positions as a result of the Democrats' takeover of the House in the Nov. 7 elections could mean more attention on device safety issues in the new Congress

You may also be interested in...



Tough Investigator And Universal-Coverage Proponent Rep. John Dingell Dead At 92

Former House Energy and Commerce Committee Chairman John Dingell Jr., D-Mich., who was a fierce investigator of federal agencies including US FDA and sponsor of the Affordable Care Act and other legislation impacting the device industry, died at age 92 Thursday at his home in Dearborn, Mich.

The New Face Of Key Congressional Committees In the 110th Session

With the new Democratic controlled Congress settling in, committee and subcommittee assignments are almost complete. Both parties have updated the ranks of most committees with device-relevant jurisdiction

The New Face Of Key Congressional Committees In the 110th Session

With the new Democratic controlled Congress settling in, committee and subcommittee assignments are almost complete. Both parties have updated the ranks of most committees with device-relevant jurisdiction

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel